Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 363 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: LDL Clear all

Conditions: Hypercholesterolemia
Interventions: Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis; Biological · Procedure
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more

Conditions: Lipid Disorders
Interventions: Not listed
Lead sponsor: The Miriam Hospital; Other
Eligibility: 18 Years to 69 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2029
U.S. locations: 2
States / cities: East Providence, Rhode Island • Providence, Rhode Island

Conditions: Hyperlipidemia
Interventions: LY3015014 IV, Placebo IV, LY3015014 SC, Placebo SC; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2013
U.S. locations: 3
States / cities: Glendale, California • Dallas, Texas • Madison, Wisconsin

Conditions: Hypercholesterolemia
Interventions: Bempedoic acid 180mg, Ezetimibe 10mg, Atorvastatin 20mg, Placebo; Drug · Other
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 11
States / cities: Champaign, Illinois • Cary, North Carolina • Charlotte, North Carolina + 7 more

Conditions: Medical Conditions to be Studied, Dyslipidemia, ASCVD Management
Interventions: Not listed
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 5,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 118
States / cities: Chandler, Arizona • Glendale, Arizona • Tucson, Arizona + 101 more

Conditions: High Cholesterol, Coronary Artery Disease
Interventions: Ezetimibe, Atorvastatin; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: San Diego, California

Conditions: Hypercholesterolemia
Interventions: Not listed
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Hypercholesterolemia
Interventions: LIB003; Drug
Lead sponsor: LIB Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Cincinnati, Ohio

Conditions: Lipid Metabolism, Inborn Errors, Hypercholesterolemia, Autosomal Dominant, Hyperlipidemias, Metabolic Diseases, Hyperlipoproteinemia Type II, Metabolism, Inborn Errors, Genetic Diseases, Inborn, Infant, Newborn, Diseases, Metabolic Disorder, Congenital Abnormalities, Hypercholesterolemia, Hyperlipoproteinemias, Dyslipidemias, Lipid Metabolism Disorders
Interventions: mipomersen, Placebo; Drug
Lead sponsor: Kastle Therapeutics, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 2
States / cities: Charlotte, North Carolina • Cincinnati, Ohio

Conditions: Peripheral Arterial Disease
Interventions: Alirocumab, Matching placebo; Drug
Lead sponsor: University of Virginia; Other
Eligibility: 35 Years to 85 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 2
States / cities: Chicago, Illinois • Charlottesville, Virginia

Conditions: Low Risk Acute Coronary Syndrome
Interventions: Stress Test, No Stress Test; Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 30 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Carotid Stenosis
Interventions: Not listed
Lead sponsor: University of Washington; Other
Eligibility: Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Employee Health and Well-being
Interventions: Workplace Wellness Program, Biometric Screening/HRA - No Compensation, Biometric Screening/HRA - Moderate Compensation, Biometric Screening/HRA - High Compensation, Wellness Activities - Low Compensation, Wellness Activities - High Compensation; Behavioral
Lead sponsor: National Bureau of Economic Research, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 4,834 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Elevated High-sensitivity C-Reactive Protein (hsCRP)
Interventions: Rosuvastatin, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years and older
Enrollment: 17,802 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 431
States / cities: Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more

Conditions: Calcinosis, Arteriosclerosis, Hyperparathyroidism, Secondary
Interventions: calcium acetate, sevelamer, atorvastatin; Drug
Lead sponsor: Nabi Biopharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: HIV Infections
Interventions: Ezetimibe; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 41
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 24 more

Conditions: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Interventions: ABT-143, simvastatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 129
States / cities: Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 110 more

Conditions: Focal Segmental Glomerulosclerosis
Interventions: LIPOSORBER® LA-15; Device
Lead sponsor: Kaneka Medical America LLC; Industry
Eligibility: Up to 75 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2029
U.S. locations: 10
States / cities: Loma Linda, California • Wilmington, Delaware • Grand Rapids, Michigan + 5 more

Conditions: Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 7,658 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 14
States / cities: Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more

Conditions: Hypercholesterolemia, Hypertension
Interventions: ETC-1002, Placebo; Drug
Lead sponsor: Esperion Therapeutics, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 143 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 34 more

Conditions: Liver Fibrosis
Interventions: Not listed
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypercholesterolemia and Hyperlipidemia
Interventions: Ketogenic Diet, Control Diet; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 39 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Dyslipidemias, Hypercholesterolemia, Familial Hypercholesterolemia, ASCVD, High Cholesterol
Interventions: Combination Therapy, Monotherapy obicetrapib, Monotherapy ezetimibe, Combination Therapy placebo, Obicetrapib Placebo, Ezetimibe Placebo; Combination Product · Drug · Other
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 45
States / cities: Gilbert, Arizona • Jacksonville, Florida • Port Orange, Florida + 37 more

Conditions: Intermittent Fasting
Interventions: Intermittent Fasting; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 21 Years to 70 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Murray, Utah

Search by objective public record fields.

Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment

Lipoprotein Interactions and Platelet Function in Healthy Individuals and Those With Lipid Disorders

A Study of LY3015014 in Healthy Participants With Elevated Low Density Lipoprotein Cholesterol

Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C

Getting to an Improved Understanding of Low-Density Lipoprotein Cholesterol and Dyslipidemia Management (GOULD) a Registry of High Cardiovascular Risk Subjects in the United States

Ezetimibe in Patients Hypo-responsive to Statins

A Real-world Study to Assess the Characteristics and Long-term Effectiveness of Inclisiran in Chinese Adult Patients

Open-Label Extension to Evaluate the Longer Term Efficacy and Safety of LIB003

Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia

A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

Low Risk Acute Coronary Syndrome

Carotid Ultrasound Sub-Study of the Familial Atherosclerosis Study-observational Study

Illinois Workplace Wellness Study

JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults

Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and Triglycerides

Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System

Patient and Provider Assessment of Lipid Management Registry

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

Development of a Novel Biomarker for Liver Fibrosis

Mechanism of Ketogenic Diet-Induced Hypercholesterolemia

Study of Obicetrapib & Ezetimibe Fixed Dose Combination on Top of Maximum Tolerated Lipid-Modifying Therapies

Weekly ONe-Day WatER-only Fasting InterventionaL Trial for Low-Density Lipoprotein Cholesterol Reduction